May 2, 2019
The biopharma industry will see seven blockbuster launches this year, according to Clarivate’s annual “Drugs to Watch” list for 2019! See how they rank: AbbVie’s upadacitinib […]
May 24, 2019
Merck struck a deal to buy Peloton Therapeutics for $1.1B upfront days before the biotech was due to list on Nasdaq. This deal will give Merck […]
May 31, 2019
A gene therapy approved by the FDA offers a potential one-time fix for a rare genetic condition known as spinal muscular atrophy that is fatal to […]
June 14, 2019
Insys Therapeutics settled with the feds for $225M on federal kickback charges, but things continue to escalate for the opioid maker. Insys filed for Chapter […]
June 14, 2019
As in past years, FiercePharma has tracked yearly data to compile the top CEO pay packages in biopharma, ranging from nearly $60M to $16M in 2018, […]
June 14, 2019
Big Pharmas are still the biggest spenders in drug R&D, and the numbers are impressive: Last year, and for the first time, the top 15 largest […]
June 14, 2019
A trio of Kendall Square buildings that are home to big-name drug companies traded hands for one of the steepest prices ever seen in Boston’s office […]
June 27, 2019
AbbVie will acquire Allergan in a $63B deal, answering questions over the company’s future beyond its top-selling drug Humira. Combined, the companies would rank as one […]
July 25, 2019
Since its U.S. approval in 2004, Pfizer’s Lyrica has topped the company’s pharma sales charts, but now its patent cliff is here. The FDA approved copycats […]